Early results of surgery for pharmacoresistant tremor in patients with Parkinson’s disease using transcranial high-inensity MRI-guided focused ultrasound

The primary results obtained from the application of focused ultrasound in patients with the pharmacoresistant tremor-predominant form of Parkinson's disease demonstrate high efficacy regarding tremor reduction and improvement in quality of life indicators during the first months of follow-up. Given that MRgFUS has only a pathogenetic effect on the mechanisms of tremor onset in PD patients and considering the steady progression of the disease, it is possible to suggest a non-persistent effect and the occurrence of limb tremor relapses in this group of patients at different follow-up periods. Despite this fact, the non-invasive, virtually outpatient method of focused ultrasound will become an integral part of the surgical treatment algorithm for pharmacoresistant tremor in PD patients, primarily due to the significant improvement in the quality of life of Parkinson's disease patients following MRgFUS thalamotomy.